In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...
Read MoreType of non Hodgkin’s lymphoma-Mantle cell lymphoma Posts on Medivizor
Searching for patients with relapsed or unresponsive non-Hodgkin lymphoma to try a new cell therapy
In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...
Read MoreManaging side effects of ibrutinib treatment
In a nutshell This study summarised the side effects of ibrutinib (Imbruvica) and how to manage them. Some background Ibrutinib is an FDA approved drug used to treat lymphoma and leukemia. It works on the immune cells in the body which may lead to many side effects. These include diarrhea, upper respiratory infections, bleeding, tiredness, and...
Read MoreEvaluating RBD chemotherapy for recurrent or non-responsive non-Hodgkin lymphoma
In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...
Read MoreSecond primary cancers in patients with non-Hodgkin lymphoma
In a nutshell This study aimed to investigate second primary cancers in patients with non-Hodgkin lymphoma. This study concluded that family history influenced second primary cancers and that second primary cancers influenced survival. Some background Non Hodgkin lymphoma (NHL) survival has improved greatly. There has been an increased...
Read MoreEvaluating the FMT regimen before a stem cell transplant in patients with aggressive non-Hodgkin lymphoma
In a nutshell This study evaluated the effectiveness of the FMT (fludarabine, melphalan, total body irradiation) regimen in patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that this regimen was well-tolerated and effective. Some background Many patients with aggressive NHL...
Read MoreThe impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads to...
Read MoreSearching for patients to try a new therapy for non-responsive lymphoma after stem-cell transplant.
In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with lymphoma lose...
Read MoreCombining ibrutinib and umbralisib to treat relapsed/unresponsive mantle cell lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive mantle cell lymphoma (MCL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in these patients. Some background Mantle cell...
Read MoreLooking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment
In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...
Read MoreEvaluating the impact of quality of life at diagnosis on patient outcomes for aggressive lymphoma
In a nutshell This study evaluated whether quality of life (QOL) scores impact outcomes for patients with aggressive lymphoma. This study concluded that QOL scores at diagnosis may predict survival outcomes for these patients. Some background The International Prognostic Index (IPI) is the most widely used tool to predict survival outcomes for...
Read MorePredicting the effects of stem cell transplant in older patients with non-Hodgkin lymphoma.
In a nutshell This study investigated the effects of stem cell transplant for non-Hodgkin lymphoma (NHL) in older patients. The main finding was that patients who responded to chemotherapy had better outcomes after stem cell transplant. Some background Stem cell transplant is often used to treat NHL. This involves the transfer of healthy cells to a...
Read More
